Industry Update: Capital market and finances

Written by Dusko ILIC

Latest developments compiled from 1 October until 30 November 2014

Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from non-academic institutions 1 October until 30 November 2014, scheduled to be published in Volume 10 Issue 2 of Regenerative Medicine.


BioTime (CA, USA; has closed the equity financing through which it received US$ 29,425,961 and certain subsidiaries received approximately US$ 1,558,905 from the sale of BioTime common shares. BioTime and the subsidiaries intend to use the net proceeds from their sales to finance clinical trials of products under development, to finance their research and development programs, and for general working capital. BioTime may invest a portion of the proceeds in one or more of its subsidiaries. Copies of the prospectus supplement, together with the accompanying prospectus, can be obtained at the SEC’s website (